Common use of Royalty Payment Period Clause in Contracts

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 on the Net Sales of Licensed Products in a given country will end on a Licensed Product-by-Licensed Product and country-by-country basis when the Licensed Product ceases to infringe or be covered by a Valid Claim within the Licensed Patents in that country. For clarity, only one royalty, determined in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Product.

Appears in 2 contracts

Samples: License Agreement (Audentes Therapeutics, Inc.), License Agreement (Audentes Therapeutics, Inc.)

AutoNDA by SimpleDocs

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 3.4 on the Net Sales of Licensed Products in a given country will end on a country-by-country, Licensed Product-by-Licensed Product and country-by-country basis when on the Licensed Product ceases to infringe later of (i) expiration, lapse, abandonment, or be covered by a invalidation of the last Valid Claim within of the Licensed Patents in that country. For clarityto expire, only one royaltylapse, determined in accordance with this Section 3.5, is payable on become abandoned or become unenforceable for the Net Sales of any unit of a applicable Licensed Product, or (ii) [*] from the first commercial sale.

Appears in 2 contracts

Samples: License Agreement, License Agreement (Audentes Therapeutics, Inc.)

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 on the Net Sales of Licensed Products in a given country will end expire on a Licensed Product-by-Licensed Product and country-by-country basis when the Licensed Product ceases to infringe or be covered by a Valid Claim within the Licensed Commercial Patents in that country. For clarity, only one royalty, determined in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Product.

Appears in 2 contracts

Samples: License Agreement (Voyager Therapeutics, Inc.), License Agreement (Voyager Therapeutics, Inc.)

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 on the Net Sales of Licensed Products in a given country will end expire on a Licensed Product-by-Licensed Product and country-by-country basis when the Licensed Product ceases to infringe or be covered by a Valid Claim within the Licensed Commercial Patents in that country. For clarity, only one royalty, determined in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Product.**** CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. CONFIDENTIAL TREATMENT REQUESTED

Appears in 1 contract

Samples: License Agreement (REGENXBIO Inc.)

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 on the Net Sales of Licensed Products in a given country will end expire on a Licensed Product-by-Licensed Product and country-by-country basis when the Licensed Product ceases to infringe or be covered by a Valid Claim within the Licensed Patents in that country****. For clarity, only one royalty, determined in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Product.**** CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. CONFIDENTIAL TREATMENT REQUESTED

Appears in 1 contract

Samples: License Agreement (REGENXBIO Inc.)

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 on the Net Sales of Licensed Products in a given country will end expire on a Licensed Product-by-Licensed Product and country-by-country basis when the Licensed Product ceases to infringe or be covered by a Valid Claim within the Licensed Patents in that country. For clarity, only one royalty, determined in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Product[***].

Appears in 1 contract

Samples: License Agreement (Voyager Therapeutics, Inc.)

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 on the Net Sales of Licensed Products in a given country will end on a country-by-country, Licensed Product-by-Licensed Product and country-by-country basis when on the Licensed Product ceases to infringe later of: (i) expiration, lapse, abandonment, or be covered by a invalidation of the last Valid Claim within of the Licensed Patents to expire, lapse, become abandoned or become unenforceable for the applicable Licensed Product in that the applicable country. For clarity, only one royalty, determined or (ii) * * * from the first commercial sale of the applicable Licensed Product in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Productapplicable country.

Appears in 1 contract

Samples: License Agreement (Rocket Pharmaceuticals, Inc.)

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 3.7 on the Net Sales of Licensed Products in a given country will end on a Licensed Product-by-Licensed Product and country-by-country basis at such time when the Licensed Product ceases to infringe or be covered by a Valid Claim within the Licensed Patents in that country. For clarity, only one royalty, determined in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Product.

Appears in 1 contract

Samples: License Agreement (Adverum Biotechnologies, Inc.)

AutoNDA by SimpleDocs

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 3.4 on the Net Sales of Licensed Products in a given country will end on a country-by-country, Licensed Product-by-Licensed Product and country-by-country basis when on the Licensed Product ceases to infringe later of: (i) expiration, lapse, abandonment, or be covered by a invalidation of the last Valid Claim within of the Licensed Patents to expire, lapse, become abandoned or become unenforceable for the applicable Licensed Product in that the applicable country. For clarity, only one royalty, determined or (ii) [*] from the first commercial sale of the applicable Licensed Product in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Productapplicable country.

Appears in 1 contract

Samples: License Agreement (Prevail Therapeutics Inc.)

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 3.3 on the Net Sales of Licensed Products in a given country will end on a country-by-country, Licensed Product-by-Licensed Product and country-by-country basis when on the later of: (i) expiration, lapse, abandonment, or invalidation of the last Valid Claim of the Licensed Patent to expire, lapse, become abandoned or become unenforceable for the applicable Licensed Product ceases to infringe in the applicable country, or be covered by a Valid Claim within (ii) ten (10) years from the first commercial sale of the applicable Licensed Patents Product in that the applicable country. For clarity, only one royalty, determined in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Product.

Appears in 1 contract

Samples: License Agreement (Jangit Enterprises, Inc.)

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 on the Net Sales of Licensed Products in a given country will end on a Licensed Product-by-Licensed Product and country-by-country basis when the Licensed Product ceases to infringe or be covered by a Valid Claim within the Licensed Commercial Patents in that country. For clarity, only one royalty, determined in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Product.

Appears in 1 contract

Samples: License Agreement (Adverum Biotechnologies, Inc.)

Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 3.3 on the Net Sales of Licensed Products in a given country will end on a country-by-country, Licensed Product-by-Licensed Product and country-by-country basis when on the Licensed Product ceases to infringe later of: (i) expiration, lapse, abandonment, or be covered by a invalidation of the last Valid Claim within of the Licensed Patents to expire, lapse, become abandoned or become unenforceable for the applicable Licensed Product in that the applicable country. For clarity, only one royalty, determined or (ii) [*] from the first commercial sale of the applicable Licensed Product in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Productapplicable country.

Appears in 1 contract

Samples: License Agreement (Prevail Therapeutics Inc.)

Time is Money Join Law Insider Premium to draft better contracts faster.